Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.

PDF link:

Vorinostat attenuates histone deacetylase (HDAC) activity, elevates acetylated histones, and impacts differentiation and apoptosis in tumor cell lines. This review outlines the toxicity, pharmacokinetic and pharmacodynamic characteristics, and efficacy of vorinostat and summarizes results from phase I studies.